QuANTUM-First: phase 3, double-blind, placebo-controlled study of quizartinib in combination with induction and consolidation chemotherapy, and as maintenance therapy in patients (pts) with newly diagnosed (NDx) FLT3-ITD acute myeloid leukemia (AML)

Journal article

Open access

Peer reviewed

R. Schlenk, H. Dombret, S. Amadori, P. Montesinos, M. Levis, M.A. Sekeres, J. Cortes, A. Perl, O. Zernovak, D. Mires, …

Annals of oncology, Vol.28, pp.v370-v370

2017-09

Files and links (1)

url

https://doi.org/10.1093/annonc/mdx373.046View

Published (Version of record) Open

4 Record Views

Title: QuANTUM-First: phase 3, double-blind, placebo-controlled study of quizartinib in combination with induction and consolidation chemotherapy, and as maintenance therapy in patients (pts) with newly diagnosed (NDx) FLT3-ITD acute myeloid leukemia (AML)
Creators: R. Schlenk - National Center for Tumor Diseases
H. Dombret - Blood Disease Department, University Hospital Saint-Louis, Paris, France
S. Amadori - University of Rome Tor Vergata
P. Montesinos - Hematology Department, Hospital Universitario La Fe, Valenica, Spain
M. Levis - Sidney Kimmel Comprehensive Cancer Center
M.A. Sekeres - Cleveland Clinic
J. Cortes - The University of Texas MD Anderson Cancer Center
A. Perl - University of Pennsylvania
O. Zernovak - Daiichi Sankyo
D. Mires - Daiichi Sankyo
N. Ge - Daiichi Sankyo
H. Zhang - Daiichi Sankyo
J. Hanyok - Daiichi Sankyo
S. Macintyre - Daiichi Sankyo
S. Gökmen - Daiichi Sankyo
K. Kobayashi - Clinical Development-Oncology, R&D, Global Oncology R&D, Daiichi Sankyo, Inc., Edison, OH, USA
H. Erba - University of Alabama at Birmingham
Publication Details: Annals of oncology, Vol.28, pp.v370-v370
Publisher: Elsevier Ltd
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
Language: English
Resource Type: Journal article
Record Identifier: 991031757727302976